CD200 (OX-2) is the ligand — a broadly expressed transmembrane protein found on neurons, endothelial cells, B cells, and tumor cells. CD200R1 (OX-2R) is the receptor — selectively expressed on myeloid cells (macrophages, DCs, microglia). CD200 binding to CD200R1 delivers an inhibitory signal to the myeloid cell, suppressing activation. For checkpoint blockade in oncology, the therapeutic approach is typically to block CD200R1 (or CD200) with an antibody, preventing CD200-mediated immunosuppression of tumor-associated macrophages.

PD-1/PD-L1 is a T-cell checkpoint — it suppresses effector T-cell function. CD200/CD200R1 is a myeloid checkpoint — it suppresses macrophage, DC, and microglial activation. The two axes regulate different arms of the immune system. In tumors with heavy myeloid infiltration (e.g., glioblastoma, pancreatic cancer), targeting the CD200/CD200R1 axis may be more effective than PD-1 blockade alone. Combination strategies targeting both T-cell and myeloid checkpoints are under active investigation.

Mice express additional CD200R family members (CD200R2/R3/R4, also called CD200RLa-d) that do not exist in humans. These mouse-specific receptors bind different ligands and have activating rather than inhibitory functions. Only CD200R1 is conserved between human and mouse and functions as the inhibitory receptor for CD200. When designing preclinical studies, ensure your anti-CD200R1 antibody is specific to CD200R1 and does not cross-react with the mouse-specific CD200R family members.

The most common functional readout is cytokine release from stimulated macrophages. Activate macrophages with LPS or IFN-γ in the presence or absence of CD200-Fc protein (agonist) or anti-CD200R1 blocking antibody. Measure TNF-α, IL-6, and IL-12 (suppressed by CD200R1 engagement) and IL-10 (may be enhanced) by ELISA or multiplex assay. You can also assess phagocytosis, ROS production, or NO release as functional readouts of myeloid activation state.

Neurons constitutively express CD200, which engages CD200R1 on microglia to maintain them in a resting surveillance state. Loss of neuronal CD200 (as occurs in neurodegeneration) or downregulation of microglial CD200R1 leads to uncontrolled microglial activation and chronic neuroinflammation. Reduced CD200R1 expression on microglia has been reported in Alzheimer's disease, Parkinson's disease, and multiple sclerosis brain tissue. CD200-Fc agonist protein is used in preclinical models to suppress neuroinflammation.